Key Takeaways
- Waiting for approval before serious commercial planning shrinks options.
- Prevalence is not the commercial opportunity.
- Access is not the same as adoption.
- Organization design should follow the market—not another company’s chart.
- Governance and ownership turn plans into execution.
Emerging biotechnology companies rarely fail commercially because their teams lack intelligence or commitment.
More often, they encounter predictable mistakes—patterns that become expensive when discovered late. A launch readiness assessment exists largely to surface those patterns while leadership can still act.
1. Treating Commercialization as a Late Event
Commercial decisions already exist during development. Waiting until NDA/BLA proximity to build market understanding, evidence strategy and organizational sequencing reduces optionality. Related: when commercial planning should begin.
2. Confusing Prevalence With Opportunity
Published epidemiology is only the beginning. Diagnosed population, eligibility, treatment rates, referral pathways and geographic accessibility determine what is commercially real.
3. Equating Coverage With Access
Favorable reimbursement creates opportunity. Patients still must navigate benefit verification, prior authorization, specialty pharmacy and support services. See market access planning before FDA approval.
4. Copying the Wrong Organization
A rare disease therapy concentrated among specialists should not automatically inherit a traditional large-field model. Organization design should follow the market. See building the commercial organization.
5. Underinvesting in Governance
Strong functional plans fail when decision rights, milestones, dependencies and escalation paths are unclear. Commercialization is an enterprise capability, not a departmental project.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
